蔡明,周振宇,曹毅,劉培超,劉宇博
(南通大學(xué)附屬醫(yī)院骨科,江蘇226001)
丹紅注射液促進(jìn)兔重建前交叉韌帶早期腱-骨愈合實(shí)驗(yàn)研究
蔡明*,周振宇,曹毅,劉培超,劉宇博
(南通大學(xué)附屬醫(yī)院骨科,江蘇226001)
目的:通過(guò)建立兔前交叉韌帶重建模型,分別對(duì)實(shí)驗(yàn)標(biāo)本進(jìn)行組織學(xué)及生物力學(xué)研究,為臨床上丹紅注射液是否能影響腱-骨愈合提供參考。方法:成年新西蘭兔20只,膝關(guān)節(jié)40個(gè),隨機(jī)分為丹紅注射液組(觀察組)及空白對(duì)照組,每組10只。所有動(dòng)物均行自體跟腱移植重建雙側(cè)前交叉韌帶。觀察組腱-骨界面注射丹紅注射液,對(duì)照組注射生理鹽水。在術(shù)后第4周、8周時(shí)處死觀察組和對(duì)照組各5只兔子。每個(gè)時(shí)間段處死的兔子中,觀察組5只兔子共10個(gè)膝關(guān)節(jié)中,取5個(gè)作組織學(xué)觀察,剩余的5個(gè)作抗拉力生物力學(xué)測(cè)試。結(jié)果:組織學(xué)觀察發(fā)現(xiàn):術(shù)后4周觀察組可見(jiàn)成纖維細(xì)胞明顯增生,以及少量排列有序的膠原纖維,同時(shí)腱骨界面可見(jiàn)少量的新血管生成,成軟骨細(xì)胞增生,肌腱和骨隧道間間隙減小。對(duì)照組骨隧道和肌腱間有新生肉芽組織和少量成纖維細(xì)胞增生,腱骨界面可見(jiàn)少量的膠原纖維,但排列疏松且不規(guī)則。術(shù)后8周觀察組骨隧道和移植肌腱間可見(jiàn)較多且排列整齊膠原纖維,腱骨界面更成熟,并可見(jiàn)類(lèi)似垂直膠原纖維。對(duì)照組腱骨界面可見(jiàn)大量成纖維細(xì)胞,膠原纖維較多排列仍不規(guī)則,腱骨界面可見(jiàn)少量骨組織生成,兩組界面形態(tài)學(xué)分布差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。術(shù)后4周觀察組腱骨界面的抗拉脫強(qiáng)度高于空白組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論:前交叉韌帶重建術(shù)后應(yīng)用丹紅注射液處理,腱骨界面成熟成纖維細(xì)胞及Sharpey樣纖維更早出現(xiàn),觀察組肌腱移植物的生物力學(xué)特性?xún)?yōu)于對(duì)照組,丹紅注射液能促進(jìn)肌腱移植物在骨隧道中的早期愈合。
膝關(guān)節(jié)前交叉韌帶損傷;前交叉韌帶重建術(shù);丹紅注射液;腱骨愈合
膝關(guān)節(jié)前交叉韌帶損傷后自復(fù)性較差,長(zhǎng)期造成膝關(guān)節(jié)的不穩(wěn),最終膝關(guān)節(jié)軟骨面及半月板遭受磨損[1]。腱-骨愈合是骨隧道與移植物之間的愈合方式,腱-骨愈合越牢固其穩(wěn)定性越高。實(shí)驗(yàn)證明骨膜、細(xì)胞生長(zhǎng)因子、骨形態(tài)發(fā)生蛋白等生物材料均能有效的加快腱-骨愈合[2-3]。但這些物質(zhì)在臨床上利用率較低,腱骨愈合和骨折愈合的過(guò)程有相似之處。實(shí)驗(yàn)證明某些活血化瘀的中藥能縮短骨折愈合的時(shí)間[4-5],推測(cè)其可促進(jìn)腱骨愈合。丹紅注射液為臨床上使用較為頻繁的活血化瘀藥物,本研究探索丹紅注射液對(duì)腱骨愈合的影響。
1.1 材料健康成年新西蘭兔20只,體重2.5~3.0kg,雌雄不限(南京市江寧區(qū)靑龍山動(dòng)物繁殖場(chǎng)繁殖,合格編號(hào):0022162,南通大學(xué)實(shí)驗(yàn)動(dòng)物中心提供)。隨機(jī)分為2組,丹紅注射液組(觀察組)和生理鹽水注射液組(對(duì)照組),各組10只新西蘭兔(20個(gè)膝關(guān)節(jié))。前交叉韌帶重建術(shù)(anterior cruciate ligament reconstruction,ACLR)后分別在股骨端及脛骨端的腱骨界面注射等量的丹紅注射液和生理鹽水注射液各0.5mL。
1.2 方法
1.2.1 動(dòng)物模型的建立:用30mg/kg巴比妥經(jīng)兔耳緣靜脈行麻醉成功后,將兔子四肢固定仰臥于操作臺(tái)上。分別做雙側(cè)下肢后內(nèi)側(cè)切口,顯露跟腱后,切取并修成長(zhǎng)約2cm,直徑約3.0mm的移植跟腱。兩端分別用4號(hào)非吸收性外科縫線鎖邊縫合,然后濕生理鹽水紗布包裹備用。分別取雙側(cè)膝關(guān)節(jié)髕韌帶內(nèi)側(cè)緣長(zhǎng)約5cm縱弧形切口,切開(kāi)關(guān)節(jié)腔。然后向外側(cè)脫位髕骨,極度屈膝切除髕下脂肪墊及周?chē)M織,并注意保護(hù)外側(cè)副韌帶,清晰暴露膝關(guān)節(jié)前交叉韌帶并切斷,查前抽屜試驗(yàn)陽(yáng)性。選取克氏針(3.0mm),在前交叉韌帶“足印區(qū)”鉆取脛骨和股骨隧道,將編織好的肌腱拉入骨隧道中。分別在股骨骨隧道口上方及脛骨骨隧道口下方冠狀位穿孔,將肌腱牽引線穿出并打結(jié)固定。觀察組動(dòng)物脛骨及股骨隧道內(nèi)均注射丹紅注射液各0.5mL,空白對(duì)照組注射等量的0.9%NaCl注射液。閉合切口,75%乙醇消毒及無(wú)菌紗布包扎。
1.2.2 術(shù)后處理:術(shù)后給予青霉素40萬(wàn)單位/天肌注,持續(xù)3天。由南通大學(xué)動(dòng)物實(shí)驗(yàn)中心籠養(yǎng),后肢不固定,自由活動(dòng)。分別在術(shù)后第4、8周隨機(jī)在2組中各處死新西蘭兔5只,每組5只兔子共10個(gè)膝關(guān)節(jié),取材并完整保留股骨及脛骨端骨段全長(zhǎng)隧道。10%中性甲醛溶液固定、10%EDTA脫鈣、浸蠟、包埋,沿著腱骨界面縱軸面切片(厚約5μm),常規(guī)HE染色觀察,剩余5個(gè)膝關(guān)節(jié)留作抗拉力測(cè)試。
1.2.3 形態(tài)學(xué)觀察及生物力學(xué)測(cè)試:(1)大體觀察:肉眼觀察重建前交叉韌帶有無(wú)壞死、變形、松動(dòng)、滑膜覆蓋劑隧道口封閉情況。關(guān)節(jié)腔內(nèi)是否有積液、粘連。(2)組織學(xué)觀察:參照Yamakado方法將界面分為4類(lèi):腱骨分離、疏松結(jié)締組織連接、sharpey纖維連接及直接連接。高倍鏡下觀察成纖維細(xì)胞的形態(tài)、新生血管及骨形成等。(3)生物力學(xué)測(cè)試:將股骨和脛骨殘端分別固定于INSTRON-4411型拉力試驗(yàn)機(jī)上。以2mm/min的速率加載,直至韌帶從骨隧道中抽出,記錄此時(shí)的最大拉力負(fù)荷。
1.3 統(tǒng)計(jì)學(xué)處理采用SPSS13.0軟件包進(jìn)行統(tǒng)計(jì)學(xué)分析,計(jì)量資料采用s表示,組間差異性比較采用配對(duì)t檢驗(yàn),計(jì)數(shù)資料組間差異性比較采用χ2檢驗(yàn),P<0.05表示差異有統(tǒng)計(jì)學(xué)意義。
2.1 標(biāo)本大體觀察術(shù)后20只實(shí)驗(yàn)動(dòng)物傷口及全身情況良好。各時(shí)間段動(dòng)物膝關(guān)節(jié)半月板及關(guān)節(jié)軟骨無(wú)磨損,未見(jiàn)膿性分泌物及其他不良情況,移植肌腱連續(xù)性完整。腱骨界面間可見(jiàn)到一定的愈合傾向。
2.2 標(biāo)本組織學(xué)觀察對(duì)照組(圖1):腱骨界面間為疏松結(jié)締組織,大量成纖維細(xì)胞,核大呈圓形,細(xì)胞混亂無(wú)固定排列,有的尚可見(jiàn)到移植肌腱和骨隧道間還有分離,少量新生血管。術(shù)后4周觀察組(圖2):腱骨界面可見(jiàn)到豐富的成纖維細(xì)胞,核大呈梭形,其中有一定量的新生血管。對(duì)照組(圖3):腱骨界面結(jié)合仍較疏松,連接主要為膠原纖維,可見(jiàn)少量軟骨細(xì)胞;腱骨界面間新生血管少。術(shù)后8周觀察組(圖4):腱骨界面間結(jié)合較緊密,可見(jiàn)排列有序類(lèi)似于sharpey纖維,還可見(jiàn)到一定量的軟骨細(xì)胞,并有明顯的軟骨陷窩;兩組均未出現(xiàn)典型直接連接形態(tài)。術(shù)后4周觀察組和對(duì)照組腱骨愈合分型比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(χ2=3,P>0.05)。術(shù)后8周兩組腱骨愈合分型比較差異有統(tǒng)計(jì)學(xué)意義(χ2=10.044,P<0.05)。觀察組腱骨界面愈合更好(表1)。
圖1 術(shù)后4周對(duì)照組腱骨界面尚有分離,可見(jiàn)疏松結(jié)締組織,成纖維細(xì)胞核呈圓形。(HE染色,100×)
圖2 術(shù)后4周觀察組腱骨界面為結(jié)締組織,成纖維細(xì)胞核呈梭形。(HE染色,100×)
圖3 術(shù)后8周對(duì)照組腱骨界面為結(jié)締組織,細(xì)胞核呈梭形的成纖維細(xì)胞,可見(jiàn)少量軟骨細(xì)胞。(HE染色,100×)
圖4 術(shù)后8周觀察組腱骨界面為致密結(jié)締組織,成纖維,細(xì)胞核呈梭形,可見(jiàn)類(lèi)似sharpey纖維及軟骨細(xì)胞并有明顯的軟骨陷窩。(HE染色,100×)
表1 各組白兔不同時(shí)期的Yamakado界面形態(tài)學(xué)分型(n=10)
2.3 生物力學(xué)檢測(cè)術(shù)后第4周觀察組平均最大拉脫負(fù)荷為48.65±4.19 N,對(duì)照組平均最大拉脫負(fù)荷為29.01±5.55 N。術(shù)后8周僅測(cè)得對(duì)照組2例平均最大拉脫負(fù)荷為79.46N,觀察組1例平均最大拉脫負(fù)荷為101.84N,因大部分為移植肌腱非隧道內(nèi)拉脫而是實(shí)質(zhì)部分?jǐn)嗔?,故只?duì)4周組的生物力學(xué)數(shù)據(jù)進(jìn)行統(tǒng)計(jì)學(xué)處理,結(jié)果所有在同一時(shí)間段,觀察組的抗?fàn)坷?qiáng)度大于對(duì)照組,兩組拉力負(fù)荷比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。
近年來(lái)隨著人們對(duì)膝關(guān)節(jié)生物力學(xué)與前交叉韌帶功能認(rèn)識(shí)的深入,對(duì)前交叉韌帶重建的觀念發(fā)生了很大的變化。美國(guó)每年需要重建膝關(guān)節(jié)前交叉韌帶的患者超過(guò)100,000例[6],但術(shù)后需進(jìn)行翻修的患者高達(dá)3000~10,000例[7]。其根本原因主要包括術(shù)后反復(fù)創(chuàng)傷、隧道定位不準(zhǔn)確、內(nèi)固定不牢固及腱骨的延遲愈合等[8]。大量動(dòng)物實(shí)驗(yàn)表明,獲得穩(wěn)定可靠的腱-骨愈合往往需要12~24個(gè)月甚至更長(zhǎng)的時(shí)間[9-10]。因此如何縮短腱骨愈合的時(shí)間就成為影響前交叉韌帶重建效果的最關(guān)鍵性因素。
腱骨愈合被定義為在移植肌腱和骨之間結(jié)構(gòu)一體和功能連續(xù)的形式[11]。腱骨愈合過(guò)程需要經(jīng)歷移植物的變性、血管再生、細(xì)胞再生等過(guò)程。正常的前交叉韌帶的止點(diǎn)具有典型的結(jié)構(gòu),包括韌帶、纖維軟骨、鈣化軟骨和骨[12]。研究表明前交叉韌帶重建術(shù)后腱-骨愈合有2種方式,一種是直接愈合(纖維軟骨止點(diǎn)),類(lèi)似于正常的纖維軟骨連接[13]。另一種是間接愈合(纖維止點(diǎn)),其特征性結(jié)構(gòu)是Sharpey纖維。一般來(lái)說(shuō)Sharpey纖維是指一些穿插性的膠原纖維將肌腱與骨隧道相連接,這種纖維通常與骨髓道的軸向垂直[14]。
促進(jìn)腱骨愈合的方法很多,包括骨膜、細(xì)胞生長(zhǎng)因子、骨形態(tài)發(fā)生蛋白等,新生血管的形成是腱骨界面組織修復(fù)時(shí)改善組織血流的基礎(chǔ)。胡安義等[15]在動(dòng)物模型上指出,丹紅注射液具有活血化瘀及保護(hù)血管內(nèi)皮的作用。馬金霞等[16]研究表明,丹紅注射液可增加血清VEGF的含量,并且能促進(jìn)新生血管的形成。良好的血供是加快腱骨愈合最基本的有利環(huán)境,腱骨愈合中另一個(gè)重要的環(huán)節(jié)是腱骨界面的骨形成。王夢(mèng)華等[5]在治療骨折時(shí)應(yīng)用丹紅注射液療效表明,丹紅能促進(jìn)血清骨源性堿性磷酸酶(ALP)的增高,反映丹紅注射液能促進(jìn)成骨活躍,進(jìn)而促進(jìn)骨折愈合及成骨作用。腫瘤壞死因子-α(TNF-α)可促進(jìn)一氧化氮(NO)的產(chǎn)生,而高濃度的一氧化氮能抑制成骨細(xì)胞的增殖,還可抑制成骨細(xì)胞的ALP活性和抑制成骨細(xì)胞合成骨鈣素等。TNF-α能刺激白介素-6(IL-6)等因子的生成,誘使破骨細(xì)胞形成,抑制ALP生成,減少細(xì)胞內(nèi)含鈣量,抑制骨的形成。王華等[17]指出丹紅能降低血清中IL-6,超敏C-反應(yīng)蛋白和TNF-α的含量,使組織壞死范圍縮小,膠原紊亂和粘液樣變性降低。有效抑制骨的吸收作用。本實(shí)驗(yàn)尚未對(duì)破骨細(xì)胞的活性進(jìn)行詳細(xì)的測(cè)定。
生物力學(xué)測(cè)試,因8周以后大部分為韌帶實(shí)質(zhì)部斷裂而非隧道內(nèi)拉脫,故只記錄4周組的生物力學(xué)數(shù)據(jù)。數(shù)據(jù)顯示丹紅組相比較對(duì)照組有更高的抗拉脫強(qiáng)度,提示丹紅組腱骨愈合強(qiáng)度高于對(duì)照組,也說(shuō)明了丹紅具有促進(jìn)腱骨愈合的作用。通過(guò)上述組織學(xué)與生物力學(xué)的研究提示,丹紅注射液對(duì)移植肌腱在骨隧道內(nèi)的早期愈合有明顯的促進(jìn)作用。由于本實(shí)驗(yàn)各組觀察的樣本量較少,觀察時(shí)間較短,術(shù)后丹紅的長(zhǎng)期持續(xù)作用仍需進(jìn)一步觀察。此外,丹紅注射液促進(jìn)腱骨愈合的具體機(jī)制、從動(dòng)物研究到臨床廣泛應(yīng)用,以及長(zhǎng)期的療效評(píng)價(jià)仍需做深入的研究。
[1]王永健,敖英芳.自體半腱肌腱移植重建前交叉韌帶移植物組織學(xué)變化的實(shí)驗(yàn)研究[J].中國(guó)運(yùn)動(dòng)醫(yī)學(xué)雜志,2004,23(6):609-612.
[2]袁本祥,董英海.骨形態(tài)發(fā)生蛋白的臨床應(yīng)用方法研究進(jìn)展[J].中華創(chuàng)傷骨科雜志,2006,8(3):268-271.
[3]曹雪華,劉昌勝,陳建國(guó).多孔磷酸鈣人工骨與重組人骨形成蛋白2復(fù)合修復(fù)骨缺損的實(shí)驗(yàn)研究[J].中國(guó)修復(fù)重建外科雜志,2006,20(9):916-919.
[4]施萊.中藥加速骨折愈合機(jī)理的研究[J].長(zhǎng)春中醫(yī)藥大學(xué)學(xué)報(bào),2010,26(4):600-602.
[5]王夢(mèng)華,呂英.丹紅注射液對(duì)新鮮骨折愈合的影響[J].浙江中醫(yī)雜志,2008,43(8):495.
[6]Griffin LY,Agel J,Albohm MJ,et al.Noncontact anterior cruciate ligament injuries:risk factors and prevention strategies[J].J AM Acad Orthop Surg,2000,8(3):141-150.
[7]Ferreti A,Conteduca F,Monaco E,et al.Revision anterior cruciate ligament reconstruction with doubled semitendinosus and gracilis tendons and lateral extra-articular reconstruction[J].J Bone Joint Surg Am,2006,88(11):2373-2379.
[8]Denti M,Lo Vetere D,Bait C,et al.Revision anterior cruciate ligament Reconstruction:causes of failure,surgical technique,and clinical results[J].Am J Sports Med,2008,36 (10):1896-1902.
[9]Rodeo SA,Arnoczky SP,Torzilli PA,et al.Tendon-healing in a bone tunnel.A biomechanical and histological study in the dog[J].J Bone Joint Surg Am,1993,75(12):1795-1803.
[10]Shelbourne KD,Carr DR.Meniscal repair compared with meniscectomy for bucket-handle medial meniscal tears in anterior cruciate ligament-reconstructed knees[J].Am J Sports Med,2003,31(5):718-723.
[11]Soon MY,Hassan A,Hui JH,et al.An analysis of soft tissue allograft anterior cruciate ligament reconstruction in a rabbit model:a short-term study of the use ofmesenchymal stem cells to enhance tendon osteointegration[J].Am J Sports Med,2007,35(6):962-971.
[12]Gao J,R?s?nen T,Persliden J,et al.The morphology of ligament insertions after failure at low strain velocity:an evaluation of ligament entheses in the rabbit knee[J].J Anat, 1996,189(Pt 1):127-133.
[13]Sharma P,Maffulli N.Tendon injury and tendinopathy: healing and repair[J].J Bone Joint Surg Am,2005,87(1): 187-202.
[14]Kawamura S,Ying L,Kim HJ,et al.Macrophages accumulate in the early phase of tendon-bone healing[J].J Orthop Res,2005,23(6):1425-1432.
[15]胡安義,劉莉.丹紅注射液對(duì)不穩(wěn)定型心絞痛患者血管內(nèi)皮功能及炎癥因子的影響[J].醫(yī)藥導(dǎo)報(bào),2011,30(3):319-321.
[16]馬金霞,魏旭明,任明芬.丹紅注射液對(duì)老年冠心病患者血管內(nèi)皮生長(zhǎng)因子濃度的影響[J].中西醫(yī)結(jié)合心腦血管病雜志,2012,10(4):399-400.
[17]王華,黃玲,陳平,等.丹紅注射液對(duì)急性腦梗死患者神經(jīng)功能、超敏C-反應(yīng)蛋白、腫瘤壞死因子-α、白細(xì)胞介素-6的影響[J].國(guó)際中醫(yī)中藥雜志,2012,34(2):116-118.
The effects on tendon-bone healing by use of Dan-Hong injection in rabbit ACL reconstruction model
CAI Ming,ZHOU Zhenyu,CAO Yi,LIU Peichao,LIU Yubo
(Department of Orthopedics,Affiliated Hospital of Nantong University,Jiangsu 226001)
Objective:To observe whether Dan-Hong injection can affect clinical tendon-bone healing,the rabbit anterior cruciate ligament reconstruction model was built and the animal experiments about histology and biomechanics were investigated.Methods:ACL reconstruction was performed on twenty healthy mature New Zealand White rabbits,with a total of 40 knees.They were randomly divided into the blank control group and the Dan-Hong injection group with 10 animals in each group.Every animal underwent the anterior cruciate ligament reconstruction operation with its Achilles tendon on both knees.Dan-Hong injection was injected into the gap of tendon-bone in the experimental groups.Nothing was used in the gap of tendon-bone in the control groups.After 4 weeks and 8 weeks of the operation,five rabbits in the experimental group and five rabbits in the control group were executed.In each period of time,five knees of the five experimental rabbits executed were taken for histological observation,and the remaining five knees were taken for biomechanical test.Results:20 rabbits survived very well,and there were no infection in the incisions.From histological observation it was found out that in 4 weeks after the operation,there was obviously visible fibroblast cells hyperplasia in the experimental group,a small number of collagen fibers were arranged orderly,there was a small amount of new angiogenesis on the tendon bone interface and there was cartilage cell proliferation.In the controls newborn granulation tissue was found between the tendon and the bone tunnel and a small amount of fibroblasts hyperplasia was observed,and there was a small amount of loose and irregular collagen fibers on the Tendon bone interface.The gap between the tendon and the bone tunnel was smaller.In 8 weeks,in the experimental group,between the transplanted tendon and the bone tunnel,there were more visible and neat rows of collagen fibers.The interface tissue was more mature and contained some analogous perpendicular collagen bundles(Sharpey fibers).In the control group tendon bone interface was visible,largenumbers of fibroblasts were seen,more collagen fibers were observed in irregular arrangement,and a small amount of bone tissue formation was found.The classification on the Yamakado type was significantly different between the two groups(P<0.05).Biomechanical examination showed that in 4 weeks the pull-out strength was stronger in the experimental group than in the control group,and there was statistical significant difference in the results(P<0.05).Conclusion:The application of Dan-Hong injection at the tendon-bone interface during ACL reconstruction resulted in the development of an intervening zone of fibro-cartilage and mature fibroblasts.The use of Dan-Hong injection was a novel method offering the potential of more physiologically earlier healing and should be conducted to improve the biomechanical strength.The present study lacks quantitative analysis of criteria,and the mechanics of the promotion of tendon-bone healing has not been absolutely clear.
Anterior cruciate ligament injury of knee joint;Anterior cruciate ligament reconstruction;Dan-Hong injection;Tendon-bone-healing
R686.5
A
p
2013-12-24
1006-2440(2014)02-0107-04